Title:
THERAPEUTIC AGENT FOR NONOBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Document Type and Number:
WIPO Patent Application WO/2020/110346
Kind Code:
A1
Abstract:
Provided is a therapeutic agent for nonobstructive hypertrophic cardiomyopathy. This therapeutic agent for nonobstructive hypertrophic cardiomyopathy contains a compound represented by formula (1) or a salt thereof.
Inventors:
HAMADA MAREOMI (JP)
Application Number:
PCT/JP2019/018298
Publication Date:
June 04, 2020
Filing Date:
May 07, 2019
Export Citation:
Assignee:
HAMADA MAREOMI (JP)
TECHNO NETWORK SHIKOKU CO LTD (JP)
TECHNO NETWORK SHIKOKU CO LTD (JP)
International Classes:
A61K31/4164; A61P9/00; A61P9/04
Other References:
HAMADA, M ET AL.: "Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy", JPN CIRC J, vol. 65, 2001, pages 531 - 538, XP055706177
HAMADA, M ET AL.: "Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy-its relationship to transmitral doppler flow profiles", CIRC J,, vol. 71, 2007, pages 1540 - 1544, XP055712944
HAMADA, MAREOMI: "Current State of Hypertrophic Cardiomyopathy: Importance of Heart Failure During Convalescence (Can the Onset of Heart Failure Be Prevented?)", MEBIO, vol. 25, no. 7, 2008, pages 86 - 93
HAMADA, M ET AL.: "Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy-its relationship to transmitral doppler flow profiles", CIRC J,, vol. 71, 2007, pages 1540 - 1544, XP055712944
HAMADA, MAREOMI: "Current State of Hypertrophic Cardiomyopathy: Importance of Heart Failure During Convalescence (Can the Onset of Heart Failure Be Prevented?)", MEBIO, vol. 25, no. 7, 2008, pages 86 - 93
Attorney, Agent or Firm:
TSUJIMARU Koichiro et al. (JP)
Download PDF: